Minoru Ohsawa

513 total citations
41 papers, 300 citations indexed

About

Minoru Ohsawa is a scholar working on Pharmacology, Public Health, Environmental and Occupational Health and Complementary and alternative medicine. According to data from OpenAlex, Minoru Ohsawa has authored 41 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pharmacology, 8 papers in Public Health, Environmental and Occupational Health and 5 papers in Complementary and alternative medicine. Recurrent topics in Minoru Ohsawa's work include Pharmacological Effects of Natural Compounds (12 papers), Plant-based Medicinal Research (6 papers) and Olfactory and Sensory Function Studies (4 papers). Minoru Ohsawa is often cited by papers focused on Pharmacological Effects of Natural Compounds (12 papers), Plant-based Medicinal Research (6 papers) and Olfactory and Sensory Function Studies (4 papers). Minoru Ohsawa collaborates with scholars based in Japan and Canada. Minoru Ohsawa's co-authors include Akiko Kikuchi, Shin Takayama, Tadashi Ishii, Ryutaro Arita, Hiroya Okano, Yoshito Ibuki, Hiroshi Shibata, Satoko Suzuki, Hideki Mizunuma and Natsumi Saito and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Scientific Reports.

In The Last Decade

Minoru Ohsawa

33 papers receiving 292 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Minoru Ohsawa Japan 11 70 65 61 40 37 41 300
Lobna Ben Mahmoud Tunisia 13 54 0.8× 41 0.6× 18 0.3× 45 1.1× 38 1.0× 29 354
Tsami Aikaterini Italy 8 24 0.3× 19 0.3× 68 1.1× 30 0.8× 36 1.0× 9 316
Mark Estes United States 16 22 0.3× 45 0.7× 40 0.7× 18 0.5× 112 3.0× 28 846
James Ker South Africa 10 15 0.2× 44 0.7× 15 0.2× 21 0.5× 15 0.4× 63 333
Jianlu Bi China 10 25 0.4× 87 1.3× 4 0.1× 31 0.8× 33 0.9× 16 329
Dana Hrnčiariková Czechia 10 12 0.2× 57 0.9× 5 0.1× 94 2.4× 33 0.9× 15 341
Daisuke Sugimoto Japan 10 16 0.2× 50 0.8× 12 0.2× 151 3.8× 51 1.4× 29 288
Matthew Dawes United Kingdom 5 15 0.2× 45 0.7× 4 0.1× 115 2.9× 78 2.1× 11 392
Mi Kyoung Lee South Korea 11 20 0.3× 29 0.4× 9 0.1× 43 1.1× 18 0.5× 43 300
Teodor Salmen Romania 11 25 0.4× 70 1.1× 4 0.1× 65 1.6× 15 0.4× 49 334

Countries citing papers authored by Minoru Ohsawa

Since Specialization
Citations

This map shows the geographic impact of Minoru Ohsawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minoru Ohsawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minoru Ohsawa more than expected).

Fields of papers citing papers by Minoru Ohsawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minoru Ohsawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minoru Ohsawa. The network helps show where Minoru Ohsawa may publish in the future.

Co-authorship network of co-authors of Minoru Ohsawa

This figure shows the co-authorship network connecting the top 25 collaborators of Minoru Ohsawa. A scholar is included among the top collaborators of Minoru Ohsawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minoru Ohsawa. Minoru Ohsawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Noda, Aoi, Ryutaro Arita, Taku Obara, et al.. (2025). Perinatal Outcomes After the Use of Kampo Medicines Containing Ephedra During Pregnancy. Pharmacoepidemiology and Drug Safety. 34(11). e70251–e70251.
2.
Arita, Ryutaro, Taku Obara, Tomofumi Ishikawa, et al.. (2025). Association of first-trimester exposure to Kampo medicines containing Prunus persica kernel with preterm birth and major congenital malformations: a Japanese database study. Frontiers in Pharmacology. 16. 1562724–1562724.
3.
Noda, Aoi, Taku Obara, Satoko Suzuki, et al.. (2024). Risk of Major Congenital Malformations Associated with the Use of Japanese Traditional (Kampo) Medicine Containing Ephedra During the First Trimester of Pregnancy. Drugs - Real World Outcomes. 11(2). 263–272. 3 indexed citations
4.
Ono, Rie, Shin Takayama, Natsumi Saito, et al.. (2024). A Case Series of Post-COVID Conditions with Fatigability Treated with Saikokeishito. An Official Journal of the Japan Primary Care Association. 47(2). 49–55. 1 indexed citations
5.
Noda, Aoi, Ryutaro Arita, Taku Obara, et al.. (2024). The Use of Japanese Traditional (Kampo) Medicines Before and During Pregnancy in Japan: The Tohoku Medical Megabank Project Birth and Three‐Generation Cohort Study. Pharmacoepidemiology and Drug Safety. 33(10). e70033–e70033. 2 indexed citations
6.
Ono, Rie, Ryutaro Arita, Shin Takayama, et al.. (2023). Progress and treatment of “long COVID” in non‐hospitalized patients: A single‐center retrospective cohort study. Traditional & Kampo Medicine. 10(2). 150–158. 4 indexed citations
7.
Akaishi, Tetsuya, Satoko Suzuki, Rie Ono, et al.. (2023). Predictors for the Development of Hypoxia or Prolonged Acute Symptoms among Non-Hospitalized Mild-to-Moderate Patients with Coronavirus Disease 2019. The Tohoku Journal of Experimental Medicine. 260(3). 231–244.
8.
Suzuki, Satoko, Taku Obara, Tomofumi Ishikawa, et al.. (2023). No association between major congenital malformations and exposure to Kampo medicines containing rhubarb rhizome: A Japanese database study. Frontiers in Pharmacology. 14. 1107494–1107494. 8 indexed citations
9.
10.
Akaishi, Tetsuya, Shigeki Kushimoto, Yukio Katori, et al.. (2022). Effectiveness of third vaccine dose for coronavirus disease 2019 during the Omicron variant pandemic: a prospective observational study in Japan. Scientific Reports. 12(1). 13589–13589. 10 indexed citations
11.
Akaishi, Tetsuya, Shigeki Kushimoto, Yukio Katori, et al.. (2022). COVID-19-Related Symptoms during the SARS-CoV-2 Omicron (B.1.1.529) Variant Surge in Japan. The Tohoku Journal of Experimental Medicine. 258(2). 103–110. 10 indexed citations
12.
Ono, Rie, Ryutaro Arita, Shin Takayama, et al.. (2022). Kampo Medicine Promotes Early Recovery From Coronavirus Disease 2019-Related Olfactory Dysfunction: A Retrospective Observational Study. Frontiers in Pharmacology. 13. 844072–844072. 5 indexed citations
13.
Suzuki, Satoko, Taku Obara, Tomofumi Ishikawa, et al.. (2021). Prescription of Kampo Formulations for Pre-natal and Post-partum Women in Japan: Data From an Administrative Health Database. Frontiers in Nutrition. 8. 762895–762895. 15 indexed citations
14.
Akaishi, Tetsuya, Michiaki Abe, Junichi Tanaka, et al.. (2021). Somatic symptoms with psychogenic or psychiatric background. SHILAP Revista de lepidopterología. 10(2). 1021–1027. 1 indexed citations
15.
16.
Toyoshima, Masafumi, et al.. (2018). Endoscopic examination of labial fusion in a postmenopausal woman: a case report. Journal of Medical Case Reports. 12(1). 26–26. 1 indexed citations
17.
Asano, Yoshitaka, Shiro Kashiwagi, Wataru Goto, et al.. (2017). Abstract P2-05-05: Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB). Cancer Research. 77(4_Supplement). P2–5. 1 indexed citations
18.
Ohsawa, Minoru, et al.. (2000). Effect of 1,25(OH)2D3 on expression of estrogen receptor-alpha mRNA on rat osteosarcoma cell line (ROS 17/2.8). Life Sciences. 66(25). 2465–2472. 1 indexed citations
19.
Takeuchi, Kazuo, et al.. (1999). Bone mineral density of epileptic patients on long-term antiepileptic drug therapy: a quantitative digital radiography study. Epilepsy Research. 33(2-3). 93–97. 30 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lobna Ben Mahmoud Breakdown of academic impact, for papers by Tsami Aikaterini Breakdown of academic impact, for papers by Mark Estes Breakdown of academic impact, for papers by James Ker Breakdown of academic impact, for papers by Jianlu Bi Breakdown of academic impact, for papers by Dana Hrnčiariková Breakdown of academic impact, for papers by Daisuke Sugimoto Breakdown of academic impact, for papers by Matthew Dawes Breakdown of academic impact, for papers by Mi Kyoung Lee Breakdown of academic impact, for papers by Teodor Salmen
Rankless by CCL
2026